How much funding has Korro raised?

Korro has raised $271.0M in total funding, most recently a Private Equity round.

Who are Korro's investors?

Korro's investors include NEA, Atlas Venture, Venrock, Deep Track Capital, Blue Owl Capital, Wu Capital.

Where is Korro headquartered?

Korro is headquartered in Cambridge, Massachusetts, United States.

What industry is Korro in?

Korro operates in Biotech, genetic medicine, RNA.

Korro

IPO

Editing RNA to rewrite the future of medicine

Public · Cambridge, United States · Founded 2019 · $271.0M raised

Biotech

genetic medicine

RNA

Headquarters: Cambridge, Massachusetts
Employees: 51–200
Founded: 2019
Business Model: B2B
Website: korrobio.com

Total Funding: $271.0M
Last Round: $85.0M Private EquityMar 2026
Rounds: 4
Type: Public

About

Korro Bio is a clinical-stage biopharmaceutical company focused on discovering, developing, and commercializing a new class of genetic medicines based on editing RNA. By leveraging endogenous RNA editing mechanisms, Korro's platform enables treatment of both rare and highly prevalent diseases. The company's lead program KRRO-110 targets alpha-1 antitrypsin deficiency (AATD). Founded in 2019 out of Atlas Venture, Korro merged with Frequency Therapeutics in 2023 and listed on Nasdaq (KRRO).

Summary

Korro is a Biotech company based in Cambridge, United States, founded in 2019. It has raised $271.0M in total across 4 rounds, most recently a $85.0M Private Equity round in Mar 2026. Investors include NEA, Atlas Venture and Venrock.

LinkedIn X (Twitter)